CI-988

CI-988 (also known as PD-134,308) is a pharmacological compound that acts as a cholecystokinin antagonist. It is primarily used in experimental research to explore the role of cholecystokinin in the brain and its potential implications in various neurological disorders and mental health conditions.

Chemistry

CI-988 is a synthetic compound that belongs to the class of benzodiazepine derivatives. Despite its structural similarity to benzodiazepines, it does not bind to benzodiazepine receptors but instead acts as a selective antagonist at the CCK_B receptor subtype of cholecystokinin.

Pharmacology

CI-988 exerts its effects by binding to the CCK_B receptor subtype, thereby inhibiting the action of cholecystokinin. Cholecystokinin is a neuropeptide that plays a crucial role in various physiological processes, including digestion, pain perception, and anxiety regulation.

Clinical Implications

Research has suggested that CI-988 may have potential therapeutic applications in the treatment of several conditions, including anxiety disorders, schizophrenia, and certain types of cancer. However, these findings are preliminary and further research is needed to confirm these potential uses.

See Also

• Cholecystokinin
• Benzodiazepine
• Neuropeptide
• Anxiety disorders
• Schizophrenia

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian